ClinicalTrials.gg
RecruitingNCT06173453JIROVECIUpdated Dec 15, 2023

Factors Associated With Survival in Patients Having Pneumocystis Jirovecii

An observational study in Pneumocystis Jirovecii Infection, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Pneumonia with a site in France — 18 open to participants now, 20 under way, 3 of them phase 3. Pneumonia · France.

Planned enrollment
24th of 56
300 · median 227
Started
2023
with 2 others
Observational
56 of 138
12 open now
Primary completion
2025-08
later than 5 of 19 live
Registered
120th of 138
by date

Among the 138 studies in Pneumonia with a site in France, this one is the 24th largest by planned enrollment of the 56 observational ones that give a count, is one of 3 that started in 2023, is one of 56 observational ones, reaches primary completion later than 5 of the 19 other live ones, and was the 120th registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

18 of the 138 studies in Pneumonia with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Pneumonia with a site in France, or all of them as a file.
02

Study summary

Pneumocystis jirovecii is a fungus that can colonize the airways of some patients and be responsible for a disease called pneumocystosis in other patients and mainly in immunocompromised patients.

Pneumocystosis was mainly linked to HIV in the 1990s, but with the advent of new immunosuppressive molecules used in cancers or autoimmune diseases and with the increase in the number of transplants, the epidemiology has changed in recent years.

Studies on P. jirovecii-related mortality are only based on patients with pneumocystosis. As a result, patients who are simply colonized or patients who are sick but not treated are not taken into account in these studies. The investigators therefore wish to study the overall mortality at six weeks and at three months in all patients with a positive sample for P. jirovecii

03

Conditions studied

  • Pneumocystis Jirovecii Infection

Keywords

  • P jirovecii Infection
  • Pneumocystis Infections
  • Pneumocystis jirovecii Infection
  • Pneumocystis jirovecii
  • Pneumonia
  • Pneumocystis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with a positive respiratory sample for P. jirovecii

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with a positive respiratory sample for P. jirovecii cared for in Strasbourg University Hospitals between 01/01/2016 and 31/12/2018. Positive samples are defined as a direct examination finding cysts or trophozoites after staining with May-Grunewald-Giemsa and/or Gomori-Grocott, a positive P. jirovecii PCR on sputum, tracheal aspirates or bronchial fluid -alveolar
  • Subject not objecting to the reuse of their data for scientific research purposes.

Exclusion criteria

Exclusion criteria:

  • Subject having expressed its opposition to the reuse of its data for scientific research purposes.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Survival at six weeks and three months after infection

    Time frame: six weeks after infection

07

Study locations

1 of 1 sites recruiting
  • Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
    Strasbourg, 67091, France
    Recruiting
    • François DANION, MD · Contactfrancois.danion@chru-strasbourg.fr · 33 3 69 55 15 88
    • François DANION, MD · Principal investigator
    • Victor GERBER, MD · Sub investigator
    • Valentin GREIGERT, Statistician · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Aug 2025, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Dec 15, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Aug 10, 2025
CompletionEst.
Oct 10, 2025
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06173453
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Jan 1, 2023
Primary completion
Aug 10, 2025 (estimated)
Completion
Oct 10, 2025 (estimated)
Last update
Dec 15, 2023

Study contacts

François DANION, MD
Contact
Francois.danion@chru-strasbourg.fr
33 3 69 55 15 88

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion